CD38 is a multifunctional protein involved in many cellular functions and has both antigenic and enzymatic properties. It catalyzes the synthesis of the calcium mobilizing messenger molecules cyclic adenosine 5'-diphosphoribose (cADPR), adenosine 5'-diphosphoribose (ADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP), which stimulate ryanodine, TRPM2, and two-pore channels, respectively. Gene knock-out experiments have shown that CD38 is closely linked to specific physiological responses that result from cADPR-dependent changes in intracellular calcium concentration. Because CD38 plays important roles in signaling pathways that may contribute to human pathologies, it is a potential target for drug development. In the past decade, considerable progress has been made toward the discovery and development of CD38 inhibitors. This review is aimed at giving a brief insight into the progress made to date about CD38 inhibitors, primarily regarding their specificity of inhibitory activity and their importance to cADPR-mediated Ca 2+ signaling.